2025 - 2026 LEGISLATURE
LRB-2442/1
CMH:emw
2025 SENATE JOINT RESOLUTION 32
April 17, 2025 - Introduced by Senators CABRAL-GUEVARA, HESSELBEIN, RATCLIFF
and SPREITZER, cosponsored by Representatives MOSES, KNODL, MELOTIK,
MURPHY, O'CONNOR, STEFFEN, CLANCY, FITZGERALD, MADISON, MIRESSE,
ORTIZ-VELEZ, PALMERI, SINICKI, STUBBS and SUBECK. Referred to Committee
on Senate Organization.
Relating to: designating the first full week in May as Tardive Dyskinesia
Awareness Week.
Whereas, serious mental illnesses like bipolar disorder, major depressive
disorder, and schizophrenia often require treatment with antipsychotic medications
for effective management, and antipsychotic prescribing rates continue to rise; and
Whereas, while prolonged antipsychotic use may be essential for the
treatment of certain conditions, it is associated with tardive dyskinesia (TD), a
condition marked by uncontrollable, abnormal, and repetitive movements of the
face, torso, limbs, or extremities; and
Whereas, people at higher risk of TD include those older than 55 years; Black
individuals; women; individuals with mood or substance use disorders, intellectual
disabilities, or central nervous system injuries; and those with high cumulative
antipsychotic exposure; and
Whereas, approximately 60 percent of the estimated 800,000 U.S. adults
1
2
3
4
5
6
7
8
9
10
11
12
13
14 2025 - 2026 Legislature - 2 - LRB-2442/1
CMH:emw
living with TD remain undiagnosed, and even mild TD symptoms can be
stigmatizing and impair physical, social, and emotional well-being, underscoring
the urgency of early screening, detection, and intervention; and
Whereas, the American Psychiatric Association recommends routine TD
screening in their clinical guidelines for antipsychotic treatment, and individuals
treated with antipsychotics or experiencing abnormal movements should consult
their health care providers to assess TD risk, receive TD screenings, and determine
appropriate treatment together; and
Whereas, FDA-approved treatments for TD can provide options for symptom
management and improved quality of life for many individuals living with TD; and
Whereas, the Wisconsin Legislature can encourage TD screening education
and awareness for health care providers, patients, and care partners to help ensure
patients prescribed antipsychotics receive care and support that aligns with clinical
best practice, including regular TD screenings; now, therefore, be it
Resolved by the senate, the assembly concurring, That the Wisconsin
Legislature designates the first full week in May as Tardive Dyskinesia Awareness
Week, underscores the importance of early detection and intervention to improve
outcomes for people living with mental health conditions and prescribed
antipsychotics, and supports efforts to raise awareness about the causes and
symptoms of TD and the importance of routine TD screening.
(END)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21